Modulation of the cytoskeleton for cancer therapy
Results: We report new function of the MT-stabilizing drug paclitaxel and the MT-destabilizing drug vinorelbine, which elucidate mechanisms beyond the canonical function of these tubulin inhibitors.
The study reports new functions for the microtubule‑stabilizing drug paclitaxel and the microtubule‑destabilizing drug vinorelbine, elucidating mechanisms beyond their canonical tubulin‑inhibitor activity, in colorectal cancer organoid models.
The findings reveal previously unknown mechanisms of these widely used chemotherapies, suggesting potential avenues for overcoming drug resistance and improving therapeutic outcomes in colorectal cancer.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics